7,564 Shares in Medpace Holdings, Inc. $MEDP Acquired by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio acquired a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 7,564 shares of the company’s stock, valued at approximately $4,006,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Proficio Capital Partners LLC bought a new stake in Medpace in the second quarter valued at about $482,000. Corient Private Wealth LP acquired a new stake in shares of Medpace in the 2nd quarter valued at approximately $2,914,000. Bank of America Corp DE bought a new position in Medpace during the 2nd quarter worth approximately $116,891,000. Strategic Global Advisors LLC bought a new position in Medpace during the 2nd quarter worth approximately $2,728,000. Finally, American Capital Management Inc. acquired a new position in Medpace during the second quarter valued at approximately $111,329,000. 77.98% of the stock is owned by institutional investors.

Medpace Trading Up 0.1%

Shares of MEDP opened at $593.39 on Friday. The stock has a market capitalization of $16.56 billion, a price-to-earnings ratio of 34.78, a PEG ratio of 2.65 and a beta of 1.15. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90. The firm has a fifty day simple moving average of $573.38 and a 200 day simple moving average of $498.87.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company’s quarterly revenue was up 17.2% on a year-over-year basis. During the same period in the prior year, the business posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

MEDP has been the subject of a number of research analyst reports. Robert W. Baird boosted their target price on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. Leerink Partners set a $620.00 target price on Medpace in a research note on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $535.00 price target on shares of Medpace in a research note on Thursday, July 23rd. Truist Financial increased their price objective on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Finally, Royal Bank Of Canada increased their target price on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $595.20.

Insider Buying and Selling

In related news, Director Brian Carley sold 5,000 shares of the firm’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total value of $3,043,150.00. Following the completion of the transaction, the director directly owned 27,825 shares of the company’s stock, valued at approximately $16,935,129.75. This trade represents a 15.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO August Troendle sold 650 shares of the business’s stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $620.27, for a total transaction of $403,175.50. Following the transaction, the chief executive officer owned 539,894 shares in the company, valued at approximately $334,880,051.38. The trade was a 0.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 134,471 shares of company stock worth $82,151,311. 20.50% of the stock is currently owned by company insiders.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.